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Tumors

Adjuvant Treatment in the
Management of Low-Grade Gliomas
Stavropoula I. Tjoumakaris, MD
Deptartment of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA

The use of chemotherapy in low-grade gliomas has been very thoroughly studied in the setting
of oligodendrogliomas and oligoastrocytomas. According to the Radiation Oncology staff here
at Thomas Jefferson University Hospital, the current practices in our institution are as follows:
Three-dimensional conformal radiation is provided in patients with low-grade gliomas 2-4 weeks
post-operatively. The total dose ranges between 50 and 54 Gy and is delivered in 1.8 fractions
at five fractions per week. In the presence of recurrence, a stereotactic boost with or without
re-operation is provided. For the most part, these practices are similar to the aforementioned
recommendations. However, factors such as the age of the patient, and optimal timing of the
radiation are not considered in our institution at this given time.
Chemotherapy is restricted to patients with known pathology of oligodendroglioma. PCV is the
chemotherapeutic agent of choice in both research recommendations and our clinical practice.
Specifically, the use of PCV in an established oligodendroglioma case has shown to increase the time
to progression and provide a statistically significant survival benefit. Furthermore, this response is
augmented in patients with chromosomal analysis positive for the 1p and 19q allele mutation. For
these patients, further chromosomal analysis is performed in order to predict the chemotherapy
response rate. Recurrent disease is managed on a patient specific basis.
There is no level I evidence on the use of chemotherapy in the remaining categories of low-grade
gliomas. A single randomized prospective trial by the South West Oncology Group studied the effect
of post-operative radiation with and without lomustine (CCNU) in low-grade gliomas; although
the median survival time of patients were 4.5 and 7.4 years respectively, the results did not reach
statistical significance and the study closed early due to slow patient accrual. The increasing use of
Temazolamide in malignant gliomas and its minimal cumulative toxicity have triggered additional
research in its use in low-grade gliomas.
An extensive medical literature search was performed on the topic of adjuvant treatment in the
management of low-grade gliomas. Although no specific guidelines were found, several papers
were reviewed that included recommendations for clinical practice. The two sets of guidelines that
were investigated were the use of adjuvant chemotherapy and radiation in low-grade gliomas. The
following five references were reviewed:
1. Lang FF, Gilbert MR: Diffusely Infiltrative Low-Grade Gliomas in Adults. J Clin Neuro 2006; 24
(8): 1236-1245.
2. Frappaz D, Chinot O, et al: Summary Version of the Standards, Options and Recommendations
for the Management of Adult Patients with Intracranial Glioma. British J of Cancer 2003; 89
(Supp I): 73-83.
3. Lesser G: Chemotherapy of Low-Grade Gliomas. Sem Rad Onc 2001; 11 (2): 138-144.
4. Dropohe E: Low-Grade Gliomas in Adults. Curr Treatm Options Neuro 2004; 6: 265-271.
5. Mason WP: Advances in the Management of Low-Grade Gliomas. Can J Neuro Sciences 2005;
32: 18-26.
A thorough review of these research articles has shown that although there are no specific
standards (guidelines) for the adjuvant treatment of low-grade gliomas, there are multiple options
and recommendations. Specifically, in the use of radiation therapy, the recommended dose is low
(between 50 and 55 Gy in daily fractions between 1.8 and 2.0 Gy at five fractions per week). This
optimal dose was reached from Class I evidence of least toxicity with equal survival benefit (EORTC
study 2284). The timing of radiotherapy was also studied and Class I data from the second EORTC
study showed that early post-operative radiotherapy prolonged the time to tumor progression at

Published by Jefferson Digital Commons, 2009

a five-year estimate from 37% (in observation
control group) to 44%. However, the benefit in
overall survival of the patients did not reach
statistical significance. Being that radiation
toxicity in this setting has not been adequately
studied, mixed options were found proposing
immediate post-operative radiation versus
radiation at the time of progression only. A
useful recommendation was to use radiation in
patients greater than 40 years of age only; this
protects the younger patient from radiation
toxicity, being that the natural progression of
the disease has a more favorable outcome in
this age bracket. The fundamental question
of whether radiation should be given in
patients with low-grade-gliomas was not
addressed in most of these studies. Most
studies provided with Class II evidence (at
best) with retrospective studies showing a fiveyear survival benefit from 10% (with surgery
alone) to 32% (with surgery and radiation).
However, most of these series have many flaws
and no options or recommendations could be
extracted from them. Most of these studies
investigated the incidence and treatment
of these tumors in the adult population.
The guidelines are different in the pediatric
population were the incidence of low-grade
gliomas is much higher, and radiation options
extremely limited secondary to the harmful
effects of radiation in the developing brain.
Similarly to radiation, all these recommendations were made for the adult population,
which is the main target population in our
institution. Chemotherapeutic agents, regimens, and overall therapy are different in the
pediatric population.
This document describes a clinical guideline
for the treatment of patients with low-grade
gliomas with radiation and chemotherapy
following surgical resection. The patient
population targeted is adults ranging from
18 to 70 years of age. All patients will be
post-operative from lesion resection the final
pathology of which should be consistent with
low-grade glioma.
Overall, radiation therapy should not be
delivered routinely following initial resection.
Based on the review paper by WP Mason,
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also PCV, although temazolamide should
be used if recurrence is characterized by
either contrast enhancement in radiographic
imaging or a higher Ki-67 labeling index
upon re-resection. Sophisticated analysis of
the RTOG 98-02 results will further refine or
change the aforementioned guidelines.
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radiation therapy benefits counteract the
deleterious effects on the brain in patients with
recurrent low-grade gliomas only. Therefore,
radiation therapy should be delivered in
patients who present with either clinical or
radiographic recurrence.
Based on level I clinical evidence provided
in the Summary Guidelines published in the
British Journal of Cancer, the total radiation
dose should be between 50 and 54 Gy divided
in 1.8 Gy fractions delivered at five fractions
per week. In the setting of the initial postoperative period, an exception is made in older
patients (greater than 40 years of age), with two
or more of the following negative prognostic
indicators: contrast enhancement, postoperative residual of large size with continuing
mass effect, rapidly increasing volume in
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follow-up imaging, uncontrolled epilepsy, and
involvement of deeper or functional structures.
Radiation therapy should be delivered in this
setting according to the aforementioned
dosing guidelines.
Chemotherapy should be delivered in all
patients with post-operative pathology
consistent with either oligodendroglioma or
oligoastrocytoma. In addition, all these patients
should undergo chromosomal analysis for the
1p 19q allele mutation. The agent of choice is
the PCV chemotherapeutic combination. In
the remaining group of low-grade gliomas,
post-operative chemotherapy should be
administered in patients presenting with
recurrence and who have had post-operative
radiation either following the initial resection
or the recurrence. The agent of choice is

These guidelines should be reviewed overall
and in an individual patient basis by an
organized oncological clinical team comprised
of neurosurgeons, radiation oncologists, and
medical oncologists. Careful adjustments
should be made on a patient-specific basis and
overall, as further research and data accrue
over the years. Careful implementation could
be achieved starting at the Medical Records
office. Patients with a post-operative diagnosis
of low-grade gliomas should be given a specific
code or tag so that if they have not been
assigned to an integrated oncological team as
an inpatient, during their post-operative office
visit, they could be referred to an oncologist
(radiation and medical) at the registration
desk. Due to the economical restrictions of
such referrals, triage nurses, guided by the
neurosurgeon’s recommendations, could
decide based on these guidelines whether one,
both, or neither referrals should be made. The
oncological team should keep frequent
correspondence on the patient clinical status
and meet at scheduled intervals to discuss the
treatment plan and adjustments thereof.
Future guidelines on adjuvant chemotherapy
will be refined from the results of the RTOG
study, which investigates the outcome of
high-risk patients with low-grade gliomas
in the setting of radiation with and without
chemotherapy (PCV). This trial closed in 2002
and the results are still maturing. The suggested
clinical guidelines provide a strong foundation
upon which additional research and clinical
testing will further refine standard of treatment.
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